Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

By Jonathan A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, C. Scott, W. Meier, R. Shapira-Frommer, T. Safra and 5 more. New England Journal of Medicine, 2012

1,667 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/129ffd8797e08f301613fdcccba9a7a47649ac27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

In Reproductive Medicine

Citations in the corpus

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, background): “1 criteria, but patients could continue olaparib beyond progression.(34) 36”
Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, methodology): “Platinum sensitivity has been used as a clinical surrogate of HR deficiency, and clinical trials of PARPis have used platinum sensitivity as an eligibility criterion for selecting patients who are enriched for HR-deficient tumors that would respond to PARPis (63, 64).”
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, background): “1 criteria, but patients could continue olaparib beyond progression [34, 36].”
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures (2017, background): “Effective PARP inhibition maintenance therapy has been demonstrated in high-grade serous ovarian cancer with germline or somatic BRCA1 or BRCA2 mutations 15 .”
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012, neutral): “The effects of experimental therapies, such as dose-dense therapy or treatment with DNA damage repair inhibitors, may similarly be evaluated in the context of gene expression signatures (39–41).”
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research (2016, background): “In breast and ovarian cancer patients di-nucleotide mutations have been found to cause a stop codon and truncation of the tumor suppressor gene BRCA1 actionable for PARP inhibitor therapy (26) but often misclassified as two inactionable missense mutations.”